SLS SELLAS LIFE SCIENCES GROUP INC US FDA Inspections 8-K Filing 2024 - Interim Analysis SELLAS Life Sciences Group announced an interim analysis by the Independent Data Monitoring Committee for its Phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia, along with a related webcast for further details.Get access to all SEC 8-K filings of the SELLAS LIFE SCIENCES GROUP INC